Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Als symbols : Amlx save search
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
Published: 2023-12-04 (Crawled : 15:30) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 0.21%
H: 4.28%
C: 1.47%
amx0035 neuroinflammatory als publication pharmaceuticals biomarkers
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -3.75%
H: 2.83%
C: 2.18%
amx0035 chmp als treatment pharmaceuticals application negative
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
Published: 2023-10-02 (Crawled : 15:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -0.05%
H: 0.55%
C: -0.98%
amx0114 relyvrio als meeting
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -1.65%
H: 0.0%
C: -5.38%
amx0035 chmp als treatment pharmaceuticals application negative
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -4.63%
H: 8.23%
C: 1.52%
amx0035 als review update treatment ongoing pharmaceuticals
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Published: 2023-02-02 (Crawled : 15:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -0.2%
H: 3.98%
C: -5.88%
amx0035 pharmaceuticals global als trial
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -0.95%
H: 5.8%
C: 3.24%
als trial
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
Published: 2022-08-03 (Crawled : 14:20) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 1.35%
H: 4.39%
C: -5.53%
amx0035 treatment fda drug als application review
Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS
Published: 2022-07-29 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 0.87%
H: 2.37%
C: 1.73%
treatment canada als
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
Published: 2022-07-06 (Crawled : 16:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 3.28%
H: 13.11%
C: 2.23%
amx0035 label extension als trial international
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
Published: 2022-07-05 (Crawled : 14:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 16.23%
H: 2.39%
C: -13.83%
amx0035 treatment fda als review
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -3.25%
H: 15.66%
C: -0.69%
treatment canada health als approval
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
Published: 2022-06-03 (Crawled : 12:20) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 36.13%
H: 4.81%
C: -7.14%
amx0035 treatment pdufa als
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
Published: 2022-05-26 (Crawled : 17:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -0.58%
H: 0.0%
C: -7.98%
als trial presentation results
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
Published: 2022-05-05 (Crawled : 18:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -0.79%
H: 1.1%
C: -7.57%
amx0035 als trial publication
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
Published: 2022-03-30 (Crawled : 00:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
| Email alert
Add to watchlist
amx0035 treatment fda als
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -3.56%
H: 6.51%
C: -33.6%
amx0035 fda sodium phenylbutyrate sclerosis als taurursodiol
Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
Published: 2022-03-18 (Crawled : 13:30) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -0.83%
H: 4.67%
C: 0.26%
amx0035 als program
Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
Published: 2022-02-25 (Crawled : 19:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: 0.73%
H: 5.65%
C: 2.31%
amx0035 treatment ema als application
Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M
|
|
| O: -3.54%
H: 5.46%
C: 0.1%
als
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.